UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 29

Sortiert nach

Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid

Clinical infectious diseases, 2020-08, Vol.71 (4), p.982-988

2020

Link zum Volltext

Verfügbarkeit prüfen

Effect of CYP2B6, ABCB1, and CYP3A5 Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study

The Journal of infectious diseases, 2010-09, Vol.202 (5), p.717-722

2010

Link zum Volltext

Verfügbarkeit prüfen

Strategies for Implementation Research to Investigate the Negative Pharmacokinetic Interaction Between Efavirenz and Dolutegravir

Clinical infectious diseases, 2021-05, Vol.72 (10), p.1823-1825

Morse, Gene D

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety and Antiviral Activity of the HCV Entry Inhibitor ITX5061 in Treatment-Naive HCV-Infected Adults: A Randomized, Double-Blind, Phase 1b Study

The Journal of infectious diseases, 2014-03, Vol.209 (5), p.658-667

2014

Link zum Volltext

Verfügbarkeit prüfen

Pharmacogenetics of Long-Term Responses to Antiretroviral Regimens Containing Efavirenz and/or Nelfinavir: An Adult AIDS Clinical Trials Group Study

The Journal of infectious diseases, 2005-12, Vol.192 (11), p.1931-1942

2005

Link zum Volltext

Verfügbarkeit prüfen

Interactions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine

Clinical infectious diseases, 2006-12, Vol.43 (Supplement-4), p.S224-S234

2006

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic Interactions between Buprenorphine and Antiretroviral Medications

Clinical infectious diseases, 2006-12, Vol.43 (Supplement-4), p.S216-S223

2006

Link zum Volltext

Verfügbarkeit prüfen

Interactions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir

Clinical infectious diseases, 2006-12, Vol.43 (Supplement-4), p.S235-S246

2006

Link zum Volltext

Verfügbarkeit prüfen

Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial

Clinical infectious diseases, 2022-10, Vol.75 (8), p.1389-1396

2022

Link zum Volltext

Verfügbarkeit prüfen

Detection of Nonnucleoside Reverse-Transcriptase Inhibitor-Resistant HIV-1 after Discontinuation of Virologically Suppressive Antiretroviral Therapy

Clinical infectious diseases, 2008-08, Vol.47 (3), p.421-424

2008

Link zum Volltext

Verfügbarkeit prüfen

Antiretroviral Therapy Intensification for Neurocognitive Impairment in Human Immunodeficiency Virus

Clinical infectious diseases, 2023-09, Vol.77 (6), p.866-874

2023

Link zum Volltext

Verfügbarkeit prüfen

Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes

Journal of antimicrobial chemotherapy, 2014-08, Vol.69 (8), p.2175-2182

2014

Link zum Volltext

Verfügbarkeit prüfen

Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy

The Journal of infectious diseases, 2020-07, Vol.222 (4), p.601-610

2020

Link zum Volltext

Verfügbarkeit prüfen

A Randomized Trial of 2 Different 4-Drug Antiretroviral Regimens versus a 3-Drug Regimen, in Advanced Human Immunodeficiency Virus Disease

The Journal of infectious diseases, 2003-09, Vol.188 (5), p.625-634

2003

Link zum Volltext

Verfügbarkeit prüfen

EDITORIAL COMMENTARY: Malaria and HIV/AIDS Interaction in Ugandan Children

Clinical infectious diseases, 2016-08, Vol.63 (3), p.423-424

2016

Link zum Volltext

Verfügbarkeit prüfen

Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage

The Journal of infectious diseases, 2018-01, Vol.217 (3), p.474-482

2018

Link zum Volltext

Verfügbarkeit prüfen

Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s

Journal of antimicrobial chemotherapy, 2017-07, Vol.72 (7), p.2042-2048

2017

Link zum Volltext

Verfügbarkeit prüfen

Impact of UGT1A1 Gilbert Variant on Discontinuation of Ritonavir-Boosted Atazanavir in AIDS Clinical Trials Group Study A5202

The Journal of infectious diseases, 2013-02, Vol.207 (3), p.420-425

2013

Link zum Volltext

Verfügbarkeit prüfen

Interactions Between Buprenorphine and the Protease Inhibitors Darunavir-Ritonavir and Fosamprenavir-Ritonavir

Clinical infectious diseases, 2012-02, Vol.54 (3), p.414-423

2012

Link zum Volltext

Verfügbarkeit prüfen

Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy

Journal of antimicrobial chemotherapy, 2014-05, Vol.69 (5), p.1370-1376

2014

Link zum Volltext

Verfügbarkeit prüfen

Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202

Journal of antimicrobial chemotherapy, 2014-12, Vol.69 (12), p.3300-3310

2014

Link zum Volltext

Verfügbarkeit prüfen

Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final Results

The Journal of infectious diseases, 2011-10, Vol.204 (8), p.1191-1201

2011

Link zum Volltext

Verfügbarkeit prüfen

Outcomes by Sex Following Treatment Initiation With Atazanavir Plus Ritonavir or Efavirenz With Abacavir/Lamivudine or Tenofovir/Emtricitabine

Clinical infectious diseases, 2014-02, Vol.58 (4), p.555-563

2014

Link zum Volltext

Verfügbarkeit prüfen

Previous Infection with Helicobacter pylori Is the Primary Determinant of Spontaneous Gastric Hypoacidity in Human Immunodeficiency Virus—Infected Outpatients

Clinical infectious diseases, 1998-10, Vol.27 (4), p.739-745

1998

Link zum Volltext

Verfügbarkeit prüfen

Safety and Antiviral Activity of the HCV Entry Inhibitor ITX5061 in Treatment-Naive HCVInfected Adults: A Randomized, Double-Blind, Phase 1b Study

The Journal of infectious diseases, 2014-03, Vol.209 (5), p.658-667

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 29

Suche als RSS-Feed

Aktive Filter

KollektionOxford University Press Journals Current

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(29)

Sprache

Englisch
(29)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Zeitschrift / Serie

Menü

Weitere Dienste

Einstellungen

Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid

Effect of CYP2B6, ABCB1, and CYP3A5 Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study

Strategies for Implementation Research to Investigate the Negative Pharmacokinetic Interaction Between Efavirenz and Dolutegravir

Safety and Antiviral Activity of the HCV Entry Inhibitor ITX5061 in Treatment-Naive HCV-Infected Adults: A Randomized, Double-Blind, Phase 1b Study

Pharmacogenetics of Long-Term Responses to Antiretroviral Regimens Containing Efavirenz and/or Nelfinavir: An Adult AIDS Clinical Trials Group Study

Interactions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine

Pharmacokinetic Interactions between Buprenorphine and Antiretroviral Medications

Interactions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir

Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial

Detection of Nonnucleoside Reverse-Transcriptase Inhibitor-Resistant HIV-1 after Discontinuation of Virologically Suppressive Antiretroviral Therapy

Antiretroviral Therapy Intensification for Neurocognitive Impairment in Human Immunodeficiency Virus

Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes

Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy

A Randomized Trial of 2 Different 4-Drug Antiretroviral Regimens versus a 3-Drug Regimen, in Advanced Human Immunodeficiency Virus Disease

EDITORIAL COMMENTARY: Malaria and HIV/AIDS Interaction in Ugandan Children

Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage

Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s

Impact of UGT1A1 Gilbert Variant on Discontinuation of Ritonavir-Boosted Atazanavir in AIDS Clinical Trials Group Study A5202

Interactions Between Buprenorphine and the Protease Inhibitors Darunavir-Ritonavir and Fosamprenavir-Ritonavir

Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy

Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202

Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final Results

Outcomes by Sex Following Treatment Initiation With Atazanavir Plus Ritonavir or Efavirenz With Abacavir/Lamivudine or Tenofovir/Emtricitabine

Previous Infection with Helicobacter pylori Is the Primary Determinant of Spontaneous Gastric Hypoacidity in Human Immunodeficiency Virus—Infected Outpatients

Safety and Antiviral Activity of the HCV Entry Inhibitor ITX5061 in Treatment-Naive HCVInfected Adults: A Randomized, Double-Blind, Phase 1b Study

Aktive Filter

Suchergebnisse filtern